Capricor Therapeutics (NASDAQ:CAPR) Given New $30.00 Price Target at Cantor Fitzgerald

Capricor Therapeutics (NASDAQ:CAPR) had its target price increased by Cantor Fitzgerald from $25.00 to $30.00 in a research note issued to investors on Thursday morning,Benzinga reports. They currently have an overweight rating on the biotechnology company’s stock.

Several other research analysts have also recently issued reports on CAPR. Maxim Group increased their price objective on Capricor Therapeutics from $12.00 to $25.00 and gave the stock a “buy” rating in a research report on Wednesday, September 25th. Oppenheimer reaffirmed an “outperform” rating and set a $15.00 price objective on shares of Capricor Therapeutics in a report on Monday, September 23rd. HC Wainwright reissued a “buy” rating and set a $40.00 price target on shares of Capricor Therapeutics in a research report on Wednesday, October 9th. Finally, Piper Sandler initiated coverage on Capricor Therapeutics in a research report on Monday, October 21st. They issued an “overweight” rating and a $35.00 price objective for the company. One investment analyst has rated the stock with a sell rating and six have issued a buy rating to the stock. According to MarketBeat, Capricor Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $34.50.

Capricor Therapeutics Stock Down 0.2 %

Shares of NASDAQ CAPR traded down $0.04 during mid-day trading on Thursday, reaching $18.45. 737,408 shares of the company were exchanged, compared to its average volume of 1,146,514. The stock has a market cap of $837.81 million, a price-to-earnings ratio of -17.44 and a beta of 4.00. The firm has a 50-day moving average of $14.63 and a 200 day moving average of $8.29. Capricor Therapeutics has a 1 year low of $2.87 and a 1 year high of $23.40.

Insiders Place Their Bets

In other Capricor Therapeutics news, major shareholder Shinyaku Co Ltd Nippon acquired 2,798,507 shares of the firm’s stock in a transaction that occurred on Friday, September 20th. The stock was acquired at an average cost of $5.36 per share, with a total value of $14,999,997.52. Following the acquisition, the insider now directly owns 7,090,351 shares of the company’s stock, valued at $38,004,281.36. This represents a 65.21 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 12.00% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Capricor Therapeutics

Several large investors have recently made changes to their positions in the business. BNP Paribas Financial Markets acquired a new stake in shares of Capricor Therapeutics during the 1st quarter valued at $40,000. Main Street Financial Solutions LLC increased its position in shares of Capricor Therapeutics by 37.5% in the second quarter. Main Street Financial Solutions LLC now owns 27,500 shares of the biotechnology company’s stock worth $131,000 after acquiring an additional 7,500 shares in the last quarter. SG Americas Securities LLC acquired a new position in Capricor Therapeutics in the 3rd quarter worth approximately $133,000. Bank of New York Mellon Corp lifted its position in shares of Capricor Therapeutics by 12.8% in the second quarter. Bank of New York Mellon Corp now owns 79,782 shares of the biotechnology company’s stock worth $381,000 after purchasing an additional 9,040 shares in the last quarter. Finally, The Manufacturers Life Insurance Company purchased a new stake in Capricor Therapeutics in the 3rd quarter worth approximately $161,000. Institutional investors own 21.68% of the company’s stock.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.